ArticlePharmacology research & perspectives2026
Damnacanthal Suppresses Breast Cancer Cells by Inducing Apoptosis and Cell Cycle Arrest via NF-ĸB Signaling.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer is the most common cancer diagnosed and the leading cause of death for women worldwide. Noni (Morinda citrifolia L.) contains an anthraquinone called damnacanthal (3-hydroxy-1-methoxy-anthraquinone-2-aldehyde), which is known to inhibit the growth of many types of cancer cells. The purpose of this study is to examine the anticancer effects of damnacanthal on cell proliferation, apoptosis, and cell cycle in breast cancer cells and its underlying signaling pathway, including nuclear factor kappa B (NF-ĸB), epidermal growth factor receptors (EGFR), and PI3K/AKT/PTEN. Damnacanthal reduced cell viability in both normal and triple-negative breast cancer cell lines, MCF-7 and MDA-MB-231, respectively. In MCF-7 cells, damnacanthal induced late apoptosis and increased cell cycle arrest in the G0/G1 and S phase, decreased RELA gene expression, and enhanced TNF-α gene expression. However, it had no effect on the protein expression of PI3K/AKT. Damnacanthal exerted anticancer activity on MCF-7 cell lines via blocking NF-ĸB (subunit p65) expression at mRNA levels in the PI3K/AKT-independent manner. These findings highlight the potential benefits of damnacanthal as a promising NF-ĸB inhibitor for cancer prevention or treatment against breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.